Divis Laboratories
Divis Laboratories Share Price Chart
Divis Laboratories last traded at ₹9,373.50 (2026-10-13). Over the past month the stock moved -0.3%, three months the stock moved +38.8%, year the stock moved +51.2%. Its closing range over 52 weeks is ₹5,856.50 – ₹9,613.00, with the latest close 2.5% below the high.
Closing prices up to 2026-10-13.
About Divis Laboratories
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
Business Overview:[1] The company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as: a) Generic APIs:[2] Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Co. is world’s largest API manufacturer for 10 generic APIs.[3] b) Custom Synthesis:[4] Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years c) Nutraceutical:[5][6] Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Divis Laboratories reported sales of ₹3,080.00 crore (+27.8%) and net profit of ₹902.00 crore (+65.5%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 3,080 | 1,255 | 41.00 | 902.00 | 33.98 |
| Mar 2026 | 2,831 | 934.00 | 33.00 | 751.00 | 28.29 |
| Dec 2025 | 2,604 | 890.00 | 34.00 | 583.00 | 21.96 |
| Sep 2025 | 2,715 | 888.00 | 33.00 | 689.00 | 25.95 |
| Jun 2025 | 2,410 | 729.00 | 30.00 | 545.00 | 20.53 |
| Mar 2025 | 2,585 | 886.00 | 34.00 | 662.00 | 24.94 |
| Dec 2024 | 2,319 | 743.00 | 32.00 | 589.00 | 22.19 |
| Sep 2024 | 2,338 | 716.00 | 31.00 | 510.00 | 19.21 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +22.5% | +25.0% | +12.2% | +13.8% | +16.1% | +12.3% | +9.5% | +27.8% |
| Operating profit growth | +49.5% | +51.9% | +21.2% | +17.2% | +24.0% | +19.8% | +5.4% | +72.2% |
| Net profit growth | +46.6% | +64.5% | +23.0% | +26.7% | +35.1% | -1.0% | +13.4% | +65.5% |
| EPS growth | +46.5% | +64.5% | +23.0% | +26.7% | +35.1% | -1.0% | +13.4% | +65.5% |
| OPM % | 31.0% | 32.0% | 34.0% | 30.0% | 33.0% | 34.0% | 33.0% | 41.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Divis Laboratories reported sales of ₹10,560.00 crore (+12.8%) and net profit of ₹2,568.00 crore (+17.2%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 10,560 | 3,441 | 33.00 | 2,568 | 96.73 |
| Mar 2025 | 9,360 | 2,973 | 32.00 | 2,191 | 82.53 |
| Mar 2024 | 7,845 | 2,210 | 28.00 | 1,600 | 60.27 |
| Mar 2023 | 7,767 | 2,370 | 31.00 | 1,824 | 68.71 |
| Mar 2022 | 8,960 | 3,885 | 43.00 | 2,960 | 111.52 |
| Mar 2021 | 6,969 | 2,867 | 41.00 | 1,984 | 74.75 |
| Mar 2020 | 5,394 | 1,826 | 34.00 | 1,377 | 51.85 |
| Mar 2019 | 4,946 | 1,874 | 38.00 | 1,353 | 50.96 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +27.1% | +9.1% | +29.2% | +28.6% | -13.3% | +1.0% | +19.3% | +12.8% |
| Operating profit growth | +47.7% | -2.6% | +57.0% | +35.5% | -39.0% | -6.8% | +34.5% | +15.7% |
| Net profit growth | +54.3% | +1.8% | +44.1% | +49.2% | -38.4% | -12.3% | +36.9% | +17.2% |
| EPS growth | +54.2% | +1.7% | +44.2% | +49.2% | -38.4% | -12.3% | +36.9% | +17.2% |
| OPM % | 38.0% | 34.0% | 41.0% | 43.0% | 31.0% | 28.0% | 32.0% | 33.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Divis Laboratories.
Get Free AI Stock Analysis FREE →Latest News
-
Divis Laboratories Ltd spurts 2.48%, rises for fifth straight session - Business Standard
-
Divis Laboratories Ltd gains for third consecutive session - business-standard.com
-
Divis Laboratories Ltd gains for third consecutive session - business-standard.com
-
Divis Laboratories Ltd gains for third consecutive session - Business Standard
-
Divis Laboratories shares rise 2.06 percent to Rs 7,397.50 - Moneycontrol.com
-
Divis Laboratories Ltd spurts 1.5%, up for five straight sessions - Business Standard
-
Divis Laboratories promoter group declares no encumbrance in FY26 - scanx.trade
-
Divis Laboratories promoter group declares no encumbrance in FY26 - scanx.trade
-
HSIE Results Daily 25/05/2026: Divis Laboratories
-
Divis Laboratories Ltd gains for third straight session - Business Standard
Frequently Asked Questions
What is the share price of Divis Laboratories today?
Divis Laboratories shares were last quoted at ₹9,373.50 (+0.4% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Divis Laboratories?
Divis Laboratories has a price-to-earnings (P/E) ratio of 86.51 and a price-to-book (P/B) ratio of 14.33. The industry P/E is 53.33.
What is the 52-week high and low of Divis Laboratories?
The 52-week high of Divis Laboratories is ₹10,000.00 and the 52-week low is ₹5,637.50.
What is the market cap of Divis Laboratories?
The market capitalisation of Divis Laboratories is about ₹253,031.38 crore.
How did Divis Laboratories perform in its latest quarterly results?
In the latest quarter (Jun 2026), Divis Laboratories reported sales of ₹3,080.00 crore (+27.8%) and net profit of ₹902.00 crore (+65.5%), compared with the same quarter last year.
Is Divis Laboratories a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Divis Laboratories has a 3-year ROE of 15.00%, 3-year profit growth of 13.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Divis Laboratories?
Promoters hold about 51.88% of Divis Laboratories.
Which sector does Divis Laboratories belong to?
Divis Laboratories belongs to the Pharmaceuticals & Drugs sector.